Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
AstraZeneca
Harvard Business School
Boehringer Ingelheim
McKesson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Gadodiamide - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for gadodiamide and what is the scope of patent protection?

Gadodiamide is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for gadodiamide. One supplier is listed for this compound.

Recent Clinical Trials for gadodiamide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dipan ShahN/A
GuerbetN/A
University of NottinghamPhase 1/Phase 2

See all gadodiamide clinical trials

Pharmacology for gadodiamide
Synonyms for gadodiamide
[N,N-bis(2-{[(carboxy-kappaO)methyl][2-(methylamino)-2-(oxo-kappaO)ethyl]amino-kappaN}ethyl)glycinato(3-)-kappa(2)N,O]gadolinium
[N,N-bis(2-{[(carboxy-kappaO)methyl][2-(methylamino)-2-(oxo-kappaO)ethyl]amino-kappaN}ethyl)glycinato(3-)-kappa(2)N,O]gadolinium--water (1/1)
0RPE15QPL0
122795-43-1
131410-48-5
131410-48-5 (parent)
131410-48-5 3H2O
2-[bis[2-[[2-(methylamino)-2-oxidanylidene-ethyl]-(2-oxidanidyl-2-oxidanylidene-ethyl)amino]ethyl]amino]ethanoate; gadolinium(3+)
2-[bis[2-[[2-(methylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+)
2-[bis[2-[[2-(methylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+); hydrate
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxo-ethyl]amino]ethyl]amino]acetate; gadolinium(3+); hydrate
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate; gadolinium(3+)
2220AH
2421AH
3688AH
410G485
84F6U3J2R6
A806259
AB0108221
AB01568258_01
AC-925
AC1L1TUZ
AC1L4BCU
AKOS015900642
AKOS015967052
AN-15426
AN-32849
APAC 826031
BC220477
BCP28893
C13106
C16H26GdN5O8
C16H26GdN5O8.xH2O
C16H26N5O8.Gd
C16H26N5O8.Gd.H2O
CAS-122795-43-1
CHEBI:31642
CHEBI:37333
CS-2254
CS-3925
CTK8E8484
D01645
D04284
DB00225
DSSTox_CID_28573
DSSTox_GSID_48647
DSSTox_RID_82845
DTXSID9048647
DV 7572
FT-0631138
Gadodiamida
Gadodiamida [INN-Spanish]
Gadodiamide (hydrate)
Gadodiamide (Omniscan)
Gadodiamide (USP/INN)
Gadodiamide [USAN:USP:INN]
Gadodiamide [USAN:USP]
Gadodiamide anhydrous
Gadodiamide hydrate
Gadodiamide hydrate Gadolinium 5,8-bis(carboxylatomethyl)-2-[2-(methylamino)-2-oxoethyl]-10-oxo-2,5,8,11-tetraazadodecane-1-carboxylate hydrate 2-[bis[2-[
Gadodiamide hydrate (JAN)
Gadodiamide(hydrate)
Gadodiamidum
Gadodiamidum [INN-Latin]
gadolinium [bis(2-{(carboxylatomethyl)[2-(methylamino)-2-oxoethyl]amino}ethyl)amino]acetate
gadolinium [bis(2-{(carboxylatomethyl)[2-(methylamino)-2-oxoethyl]amino}ethyl)amino]acetate--water (1/1)
gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate
gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate hydrate
Gadolinium 5,8-bis(carboxylatomethyl)-2-[2-(methylamino)-2-oxoethyl]-10-oxo-2,5,8,11-tetraazadodecane-1-carboxylate hydrate
Gadolinium-DTPA-BMA
Gadolinium, (5,8-bis((carboxy-kappaO)methyl)-11-(2-(methylamino)-2-(oxo-kappaO)ethyl)-3-(oxo-kappaO)-2,5,8,11-tetraazatridecan-13-oato(3-)-kappaN5,kappaN8,kappaN11,kappaO13)-
Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)- 3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate
Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate
gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate hydrate
gadolinium(III) 5,8-bis(carboxylatomethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oate
Gd DTPA-BMA
HSDB 7547
HY-B0266
HY-B0787
J-004857
J10385
K-4104
KS-00001F70
LS-186651
LS-70966
MOLI001033
NCGC00182547-01
NCGC00182547-02
NCGC00184996-01
Omniscan
Omniscan (TN)
RT-013070
S 041
s1751
SC-19852
SCHEMBL3175139
SCHEMBL73031
TL8000744
Tox21_112999
Tox21_113000
Tox21_113000_1
UNII-0RPE15QPL0
UNII-84F6U3J2R6
VA10992

US Patents and Regulatory Information for gadodiamide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for gadodiamide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Merck
McKinsey
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.